Caspofungin

CHEMBL1630575 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1093.3 g/mol

LogP

0.3

Phase

4

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Peso Molecular

1093,3000 g/mol

LogP

0,30

TPSA

412,00 Å²

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Non-Alcoholic Fatty Liver Disease Obesity Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O

InChI

InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-/m0/s1

Molecular Formula

C52H88N10O15

HBD / HBA

16 / 18

Ligações Rotacionáveis

23

Átomos Pesados

77

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Yes, Caspofungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1630575. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16119814. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Caspofungin no PillFYI

Estrutura

Dados Rápidos

Fórmula: C52H88N10O15
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.